In this video soundbite from the ERS-ISIAN 2025 symposium, Dr. Vibeke Backer discusses how Type 2 inflammation drives severe, uncontrolled CRSwNP. It covers key immune cells and biomarkers (e.g., IL-4, IL-5, IL-13, TSLP), global prevalence differences, and the importance of symptom tracking and targeted therapies.
Professors Bouaziz, Paller, and Irvine discuss the clinical burden of atopic dermatitis, the biomarkers of subclinical control, and evidence of potential disease modification in AD at EADV 2025.

Dr. Eric Simpson discusses the differing goals of patients and physicians in treating atopic dermatitis and emphasizes the importance of patient input.

In this video from the April 2025 WCPD symposium, Dr Paula Luna discusses the multidimensional disease burden in pediatric patients with AD and the data regarding how early intervention may lead to long-term disease control and a reduced risk of developing non-atopic comorbidities.

Join Christine Bangert, Mark Boguniewicz and Perla Lansang for an educational symposium on atopic dermatitis (AD) in children, exploring the diagnosis and pathophysiology of AD in children, the life-long effects of uncontrolled disease beyond the skin, and current and emerging therapies.

Review a patient case to learn more about identifying uncontrolled asthma and type 2 inflammation in pediatric patients

In this video clip from the EAACI 2024 symposium, Dr. Mullol discusses the challenge of defining active nasal disease using an endoscope.
Review a severe asthma patient case to learn more about assessing asthma control and on-treatment clinical remission.

Dr. Amy Paller discusses the evolving concepts of early intervention and disease modification in AD and describes potential biomarkers of subclinical control at EADV 2025.

This video of the October 2024 ADVENT symposium at EAPS in Vienna, Austria features Drs Christine Bangert, Mark Boguniewicz, and Perla Lansang as they discuss the inflammatory processes driven by type 2 cytokines that lead to AD and atopic comorbidities, the multidimensional and cumulative disease burden associated with AD and its comorbidities, and the current and emerging treatment options for children with AD uncontrolled with topical therapy

Prof. Thomas Bieber explores early intervention and disease modification in atopic dermatitis.

Join Prof. Hellings and Prof. Corso in dicussion on the factors affecting complete control of CRSwNP, including treatment types, comorbidities, and the need for more data on biologics.